Organization
Nanning, China
3 abstracts
Abstract
Phase II study of tislelizumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer.Org: Nanning, China,
Abstract
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,
Abstract
Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC).Org: Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Guangxi Medical University Cancer Hospital, Nanning, China,